Litcius/Paper detail

Selumetinib in adults with NF1 and inoperable plexiform neurofibroma: a phase 2 trial

Andrea M. Gross, Geraldine O’Sullivan Coyne, Eva Dombi, Cecilia Tibery, William G. Herrick, Staci Martin, Steven P. Angus, Jack F. Shern, Steven D. Rhodes, Jared C. Foster, Larry Rubinstein, Andrea Baldwin, Christopher Davis, Shelley A.H. Dixon, Margaret Fagan, Mary Jane Ong, Pamela L. Wolters, Mary Anne Tamula, Olivia H. Reid, Hari Sankaran, Fang Fang, Jeevan Prasaad Govindharajulu, Alice T. Browne, Rosandra N. Kaplan, Kara Heisey, Thomas J. On, Xiaoling Xuei, Xiyuan Zhang, Barry C. Johnson, Ralph E. Parchment, D. Wade Clapp, Apurva K. Srivastava, James H. Doroshow, Alice P. Chen, Brigitte C. Widemann

2025Nature Medicine38 citationsDOIOpen Access PDF

Topics & Concepts

SelumetinibMedicineNeurofibromatosisAdverse effectDysgeusiaInternal medicineRashPediatric cancerCancerOncologySurgeryPathologyColorectal cancerKRASNeurofibromatosis and Schwannoma CasesSarcoma Diagnosis and TreatmentBone Tumor Diagnosis and Treatments
Selumetinib in adults with NF1 and inoperable plexiform neurofibroma: a phase 2 trial | Litcius